First-line treatment with the combination of palbociclib plus letrozole extended progression-free survival by approximately 50% in patients with metastatic estrogen receptor–positive, HER2-negative breast
cancer, according to final results of the PALOMA-1 trial, a randomized phase II study presented at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego.